autifony

News

Autifony Therapeutics receives Orphan Drug Designation for AUT00206 for Fragile X Syndrome

Stevenage, UK -  10 July 2017 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced that the U.S. Food and Drug Administration (FDA) has granted AUT00206 an Orphan Drug Designation for the treatment of Fragile X Syndrome, the most common known cause of inherited learning disabilities.

Read more